Background: Patients are treated with statins for the control of cholesterol; but statins control only low-density lipoprotein (LDL) and not non-high-density lipoprotein (non-HDL). Also, LDL is not a good coronary risk predictor. That creates the necessity to find a better biomarker for future coronary risk prediction. Hence, biomarkers under this territory such as total cholesterol (TC)/HDL, LDL/HDL, triglyceride (TG)/HDL ratios, non-HDL, apolipoprotein-B (apo-B), and high-sensitivity C-reactive protein (hs-CRP) were to be assessed and correlated with LDL to find the better biomarker in Indian patients. Objective: The objective was to study non-HDL, apo-B, TC/HDL, TG/HDL, LDL/HDL ratios, and hs-CRP in patients under statin therapy; and to correlate them with their LDL; to predict the risk of future coronary events; and to identify which biomarker among them is better at detecting the same. Materials and Methods: This is a cross-sectional observational study performed by systematic random sampling among 87 patients under statin therapy, and the levels of LDL, TC/HDL, LDL/HDL, TG/HDL ratios, non-HDL, apo-B, and hs-CRP were measured in such patients, and their correlation with optimized and unoptimized LDL groups were done. Continuous data were represented as mean and standard deviation, and P value was calculated using independent t-test or z-test. Results: Non-HDL, TC/HDL, and LDL/HDL ratios were found to be statistically significant -all three parameters with P < 0.0001 in predicting the coronary artery disease attacks in the future. Conclusion: Even though all patients in our study were under statin therapy, they are still under the risk of developing coronary events. This can be solved by targeting the control of non-HDL or TC/HDL or LDL/HDL ratios, as they are found be better biomarkers for future coronary risk prediction. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
INTRODUCTION
Asian Indians, whether living in India or elsewhere, have a higher incidence of developing coronary artery Coronary risk prediction by the correlation of total cholesterol/high-density lipoprotein, triglyceride/high-density lipoprotein, low-density lipoprotein/high-density lipoprotein ratios, non-high-density lipoprotein, apolipoprotein-B, and high-sensitivity C-reactive protein with low-density lipoprotein in Indian patients under statin therapy disease (CAD) when compared to other ethnic groups. [1] There is an urgent need to put a hold to these increasing figures. Here is where statin therapy comes into play. [2] However, statins control only low-density lipoprotein (LDL) and not non-high-density lipoprotein (non-HDL). Controlling just LDL would not help, as it cannot be considered a reliable biomarker for future coronary risk prediction. [3] This has created a vacuum for identification of a reliable biomarker which could help in future coronary risk prediction. Total cholesterol (TC)/HDL, LDL/HDL, triglyceride (TG)/HDL ratios, non-HDL, apolipoprotein-B (apo-B), and high-sensitivity C-reactive protein (hs-CRP) are other biomarkers under this category which could help to analyze this risk. However, the better future coronary risk predictor among the above-mentioned markers had to be studied.
MATERIALS AND METHODS
This is a cross-sectional observational study, with systematic random sampling done among a sample size of 87 patients of ages between 35 and 85 years old, who attended as outpatients to, or were inpatients of the Department of General Medicine in Sri Manakula Vinayagar Medical College and Hospital, Pondicherry, India; within a period of around 8 months, between December 2017 and July 2018. Informed written consent was obtained from all the participants, and the Institutional Ethics Committee approval was obtained for performing the study. Blood samples of around 6 mL were taken from the study group at presentation in ethylenediaminetetraacetic acid (EDTA) tubes obtained through antecubital venous access.
The TC, HDL, and TGs were measured after overnight fasting, using ChemWell 2910 autoanalyzer. Meanwhile, the LDL was measured using the Friedewald formula (LDL = TC -HDL-TG/5) which is internationally accepted. Apo-B was measured using Fine Test ELISA Kit, and hs-CRP was measured using Diagnostic Canada Inc., ELISA kit. Non-HDL was obtained by the deduction of HDL from TC. TC/HDL, LDL/HDL, and TG/HDL ratios were obtained from the above-mentioned results.
Statistical analysis
Data were entered into Microsoft Excel data sheet and were analyzed using SPSS version 22.0 (IBM SPSS Statistics, Somers NY, USA) software. Continuous data were presented as mean and standard deviation, and P value was calculated using independent t-test or z-test after assuming all the rules of statistical tests. Patients were divided into two groups -those with optimized LDL and unoptimized LDL. Biomarkers such as non-HDL, hs-CRP, apo-B, TC/HDL, TG/HDL, and LDL/HDL ratios were selected (based on the previous studies as biomarkers for coronary risk prediction) to be correlated with the two mentioned LDL groups in Indian patients to assess the better biomarker among them.
RESULTS
A total of 87 patients were included in the study, among whom 62.1% had optimized LDL levels, and in the remaining 37.9%, LDL levels were not optimized [ Table 1 ]. The mean age of the study group was 60.66 years. While 62.06% of the study group comprised males and 37.94% were females.
Non-HDL, TC/HDL ratio, and LDL/HDL ratio were found to be statistically significant; with all three parameters having P < 0.0001 in predicting the CAD attacks in the future.
The area under the receiver operating characteristic (ROC) curve [ Figure 1 ] was found to be more for non-HDL-C when compared with other parameters and was found to be a better biomarker in prediction of future CAD. The area under the ROC curve for non-HDL-C, TC/HDL ratio, and TG/HDL ratio were found to be statistically significant in predicting CAD attacks in the future [ Table 2 ]. CAD and 5.7 million to stroke. [4] In India, the incidence of CAD has doubled in the past 25 years. There is an urgent need to put a hold to these increasing figures. Here is where On comparison of the non-HDL levels with LDL cholesterol levels, it was found that, a significant proportion of the patients despite having been on statin therapy, had high unoptimized LDL levels with high non-HDL levels (21.2% in the unoptimized LDL group had a non-HDL of borderline high and 6.1% of those in unoptimized LDL had a non-HDL of high), with a P < 0.0001, as seen in Table 3 .
When TC/HDL ratio was compared with LDL levels, it was found that, 76% of them with optimized LDL-C and 64% with an unoptimized LDL-C level had a moderately high level of TC/HDL ratio. Similarly, 3.9% of the patients with optimized LDL-C and 36% patients of the un-optimized LDL-C group had high levels of TC/HDL ratio. Moreover, these values were statistically significant with P < 0.0001, as shown in Table 4 .
As shown in Table 5 , the LDL/HDL ratio was also compared with LDL-C; and was found that, 32.1% of the patients with optimized LDL-C, and 51.7% of those with unoptimized LDL-C had a moderately high level of LDL/HDL ratio. Whereas, 3.8% of those with optimized LDL-C and 48.3% of those with unoptimized LDL-C had a high level of LDL/HDL. Even these values were statistically significant, with P < 0.0001.
Gender-based analysis of LDL-C and non-HDL-C revealed the fact that both LDL-C and non HDL-C were found to be high in males, rather than in females; with a P value of 0.088 and 0.02, respectively; as depicted in Figures 2 and 3 .
The levels of hs-CRP, apo-B, and TG/HDL ratio were not statistically significant in helping assess the future coronary risk events, with P values of 0.441, 0.188, and 0.599, respectively, according to our study as shown in Tables 6-8 , respectively.
DISCUSSION
Cardiovascular disease accounts for approximately 17.5 million deaths annually, and of these, 7.6 million are attributed to Increased attention to the metabolic syndrome and diabetes, including the inaccuracy of the LDL-C measurement in these patients because of elevated TGs was highlighted. [5] According to a study conducted by Thanassoulis et al., statin was more closely related to reductions in apo-B than to reductions in either non-HDL or LDL. [6] Using the Friedewald equation for LDL, ignores the important atherogenic VLDL remnants as targets for therapy. Meanwhile, the VLDL remnants, as well as the atherogenic IDL, LDL, and TGs, are accounted for using the simple non-HDL calculation which is TC -HDL. [7] Non-HDL incorporates all cholesterol in potentially atherogenic lipoprotein particles, VLDL, IDL, LDL, and lipoprotein (a). Another study conducted by Boekholdt et al. concluded that changes in non-HDL-C also explained a larger proportion of the atheroprotective effect of statin intervention than did LDL cholesterol and apo-B. [8] Although it was previously believed that LDL was the most atherogenic lipoprotein and thus became the target for therapy surveillance, it is now realized that all of these lipoproteins confer some atherogenic potential. The total apo-B level indicates the total number of lipoprotein particles in LDL, IDL, and VLDL. Since most apo-B containing particles are atherogenic, it was hypothesized that the total apo-B concentration should be a better predictor of coronary heart disease (CHD) risk than LDL according to earlier studies. [9] A few other studies have shown that a high LDL/HDL ratio with a high TG level has the highest CHD development risk. But because the measurement of VLDL is missed when just this (ratio of LDL/HDL and measurement of high TG) is done in patients with high VLDL with elevated triglycerides, a mere measurement of LDL/HDL ratio may not be accurate, and so the TC/HDL ratio was studied for, and was found to be a better predictor for identifying risk of development of ischemic heart disease. [10] Whereas, a few other studies showed that, the abnormal ratio of TG/HDL was found to be the single most powerful predictor of extensive CHD among all the lipid variables examined. [11] In a study conducted by Ray et al., the analysis of acute coronary syndrome patients receiving statin therapy apo-B/AI, TC/HDL ratios, non-HDL, and LDL all provided similar information on risk prediction, however, the addition of hs-CRP to lipid-based measurements significantly improved the risk prediction. [12] Most of these studies were not done in India. As most of the aforementioned studies were done in the West, and as the Indian diet varies drastically from the diet of that of the Western world, and an Indian study is necessary at this juncture to assess the better biomarker which could help for the coronary risk prediction among TC/HDL, LDL/HDL, TG/HDL ratios, non-HDL, and apo-B. This study was carried out with this intent.
In our study, we found that both the TC/HDL and LDL/HDL ratios were found to be reliable in predicting the future coronary risk; as they uncovered the future coronary risk even in patients with optimized LDL-C. Non-HDL-C levels were also helpful in detecting future coronary risk; albeit with a lesser reliability. However, other parameters such as apo-B, hs-CRP, and TG/HDL ratio were not statistically significant in detecting the future coronary events.
CONCLUSION
Based on our study, what we propose is, to assess a patient's future coronary risk prediction, measurement of LDL-C alone is insufficient. It is best to measure his/her TC/HDL ratio or LDL/HDL ratio or non-HDL-C levels to detect the future coronary risk and to target and control these parameters to reduce any coronary risk development in the future.
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